» Articles » PMID: 32906817

Cholestasis Differentially Affects Liver Connexins

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Sep 10
PMID 32906817
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Connexins are goal keepers of tissue homeostasis, including in the liver. As a result, they are frequently involved in disease. The current study was set up to investigate the effects of cholestatic disease on the production of connexin26, connexin32 and connexin43 in the liver. For this purpose, bile duct ligation, a well-known trigger of cholestatic liver injury, was applied to mice. In parallel, human hepatoma HepaRG cell cultures were exposed to cholestatic drugs and bile acids. Samples from both the in vivo and in vitro settings were subsequently subjected to assessment of mRNA and protein quantities as well as to in situ immunostaining. While the outcome of cholestasis on connexin26 and connexin43 varied among experimental settings, a more generalized repressing effect was seen for connexin32. This has also been observed in many other liver pathologies and could suggest a role for connexin32 as a robust biomarker of liver disease and toxicity.

Citing Articles

Impact of partial bile duct ligation with or without repeated magnetic resonance imaging examinations in mice.

Chen T, Zhou Z, Liu J, Zheng L, Wang Z, Zhang X Sci Rep. 2022; 12(1):21014.

PMID: 36470922 PMC: 9722823. DOI: 10.1038/s41598-022-25318-8.


Expression of connexins and pannexins in diseased human liver.

Leroy K, Vilas-Boas V, Gijbels E, Vanderborght B, Devisscher L, Cogliati B EXCLI J. 2022; 21:1111-1129.

PMID: 36381643 PMC: 9650699. DOI: 10.17179/excli2022-5163.


Blocking connexin 43 and its promotion of ATP release from renal tubular epithelial cells ameliorates renal fibrosis.

Xu H, Wang M, Li Y, Shi M, Wang Z, Cao C Cell Death Dis. 2022; 13(5):511.

PMID: 35641484 PMC: 9156700. DOI: 10.1038/s41419-022-04910-w.


Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels.

Cooreman A, Caufriez A, Tabernilla A, Van Campenhout R, Leroy K, Kadam P Int J Mol Sci. 2022; 23(9).

PMID: 35563409 PMC: 9103705. DOI: 10.3390/ijms23095018.


The altered osteocytic expression of connexin 43 and sclerostin in human cadaveric donors with alcoholic liver cirrhosis: Potential treatment targets.

Jadzic J, Milovanovic P, Cvetkovic D, Zivkovic V, Nikolic S, Tomanovic N J Anat. 2022; 240(6):1162-1173.

PMID: 34978341 PMC: 9119608. DOI: 10.1111/joa.13621.


References
1.
Nakashima Y, Ono T, Yamanoi A, El-Assal O, Kohno H, Nagasue N . Expression of gap junction protein connexin32 in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Gastroenterol. 2004; 39(8):763-8. DOI: 10.1007/s00535-003-1386-2. View

2.
Neveu M, Hully J, Babcock K, Vaughan J, Hertzberg E, Nicholson B . Proliferation-associated differences in the spatial and temporal expression of gap junction genes in rat liver. Hepatology. 1995; 22(1):202-12. View

3.
Cogliati B, Crespo Yanguas S, Da Silva T, Aloia T, Nogueira M, Real-Lima M . Connexin32 deficiency exacerbates carbon tetrachloride-induced hepatocellular injury and liver fibrosis in mice. Toxicol Mech Methods. 2016; 26(5):362-370. PMC: 5417356. DOI: 10.1080/15376516.2016.1190991. View

4.
Traub O, Look J, Dermietzel R, Brummer F, Hulser D, Willecke K . Comparative characterization of the 21-kD and 26-kD gap junction proteins in murine liver and cultured hepatocytes. J Cell Biol. 1989; 108(3):1039-51. PMC: 2115368. DOI: 10.1083/jcb.108.3.1039. View

5.
Woolbright B, Jaeschke H . Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro. Methods Mol Biol. 2015; 1250:363-76. PMC: 4765948. DOI: 10.1007/978-1-4939-2074-7_28. View